Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.13M | 10.54M | 11.63M | 18.85M | 5.79M |
| Gross Profit | 7.10M | 5.97M | 4.46M | 8.60M | 2.51M |
| EBITDA | -5.44M | -4.93M | -18.67M | -10.69M | -10.41M |
| Net Income | -8.59M | -8.97M | -45.72M | -15.03M | -9.28M |
Balance Sheet | |||||
| Total Assets | 26.84M | 25.42M | 36.94M | 97.99M | 30.28M |
| Cash, Cash Equivalents and Short-Term Investments | 6.48M | 3.02M | 7.98M | 44.89M | 850.93K |
| Total Debt | 8.06M | 9.79M | 7.19M | 7.20M | 3.24M |
| Total Liabilities | 19.73M | 15.92M | 19.05M | 39.71M | 8.12M |
| Stockholders Equity | 7.11M | 9.50M | 17.89M | 58.28M | 22.16M |
Cash Flow | |||||
| Free Cash Flow | 848.00K | -9.79M | -22.39M | -16.77M | -10.28M |
| Operating Cash Flow | 946.00K | -9.64M | -18.04M | -10.89M | -3.76M |
| Investing Cash Flow | -98.00K | 4.31M | -4.36M | -8.33M | -6.52M |
| Financing Cash Flow | 2.63M | 652.00K | -10.92M | 63.27M | 8.12M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Lumos Diagnostics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$45.66M | ― | -51.49% | ― | 80.84% | 57.59% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
45 Neutral | AU$25.25M | ― | -104.23% | ― | ― | -17.26% | |
45 Neutral | AU$90.86M | ― | -47.52% | ― | 44.61% | 16.40% | |
45 Neutral | AU$42.14M | ― | -39.07% | ― | 26.07% | 0.85% | |
40 Underperform | AU$15.39M | ― | -71.10% | ― | ― | 76.17% | |
38 Underperform | AU$49.44M | ― | -33.42% | ― | 158.37% | 36.73% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics Holdings Ltd. has released a presentation intended for informational purposes, emphasizing that it should not form the basis of any investment decisions. The document contains disclaimers about the accuracy and reliability of the information provided, highlighting that it includes forward-looking statements subject to risks and uncertainties. The company advises stakeholders to seek independent professional advice before making investment decisions, as the document is not a prospectus or an offer to acquire securities.
Lumos Diagnostics reported a 12% increase in FY25 revenue, reaching US$12.4 million, despite a 26% quarterly revenue drop due to the end of the U.S. flu season. The company is advancing its FebriDx CLIA Waiver Study and has secured a significant distribution agreement with PHASE Scientific in the U.S. Additionally, Lumos has expanded its development agreement with Hologic, which is expected to generate additional revenue, and secured a loan facility to support working capital needs.
Lumos Diagnostics Holdings Ltd. has announced a proposed issue of 19,616,000 ordinary fully paid securities, with the issuance date set for September 1, 2025. This strategic move is expected to bolster the company’s financial position, potentially enhancing its market competitiveness and providing additional resources for its ongoing projects and initiatives.
Lumos Diagnostics has secured a A$5.0 million loan facility from major shareholders Tenmile Ventures and Ryder Capital to support its efforts in obtaining a CLIA waiver for its FebriDx® product from the FDA. This financial move is part of a broader strategy to maintain momentum towards commercialization while minimizing equity dilution. Additionally, Lumos has entered into a significant distribution agreement with PHASE Scientific, valued at US$317 million, contingent upon achieving the CLIA waiver. This agreement marks one of the largest distribution deals for an ASX-listed diagnostics company and is expected to provide substantial funding alongside the loan facility to meet Lumos’s working capital needs.
Lumos Diagnostics Holdings Ltd. has released an investor briefing document, emphasizing that the information provided is solely for informational purposes and not intended as a basis for investment decisions. The document includes disclaimers regarding the accuracy and reliability of the information, highlighting the inherent risks and uncertainties in market data and forward-looking statements. Lumos advises recipients to seek independent professional advice before making investment decisions, as the document does not constitute financial advice.
Lumos Diagnostics Holdings Ltd, a leader in rapid point-of-care diagnostic technologies, has announced an exclusive U.S. distribution agreement for its FebriDx product with PHASE Scientific. This strategic partnership is expected to enhance Lumos’s market presence in the U.S., potentially improving its operational capabilities and offering significant benefits to its stakeholders.
Lumos Diagnostics Holdings Limited, listed on the Australian Securities Exchange, has announced the lifting of its trading suspension following the release of a significant strategic agreement. This development is expected to have a positive impact on the company’s market operations and stakeholder confidence, as it signifies a potential turning point in its strategic positioning.
Lumos Diagnostics has signed a significant six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® product in the U.S. market, valued at up to US$317 million. This agreement marks a pivotal moment for Lumos, as it provides a clear pathway for FebriDx® to enter the U.S. market, pending a CLIA waiver from the FDA. The partnership with PHASE Scientific, known for its rapid diagnostics brand INDICAID®, is expected to enhance the adoption of FebriDx® in urgent care settings, potentially transforming rapid respiratory diagnostics and clinical decision-making.
Lumos Diagnostics Holdings Ltd. has requested a voluntary suspension of its securities on the Australian Securities Exchange pending a significant announcement related to strategic material agreements. This suspension is intended to help the company manage its disclosure obligations, with expectations to release the announcement before the next trading session, potentially impacting its market positioning and stakeholder interests.
Lumos Diagnostics Holdings Ltd. has requested a trading halt on its securities on the Australian Securities Exchange pending an announcement related to strategic material agreements. This move is intended to manage the company’s continuous disclosure obligations and is expected to conclude by the start of normal trading on July 15, 2025, or upon the release of the announcement. The trading halt reflects the company’s proactive approach to compliance and transparency, potentially impacting its market positioning and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the cessation of certain securities due to unmet conditions or expiration. This development may impact the company’s capital structure and could influence investor perceptions, as it reflects on the company’s ability to meet certain financial or operational milestones.
Lumos Diagnostics has received a cash refund of A$215,485 under the Australian Government’s Research and Development Tax Incentive for its FY2024 efforts. This refund supports Lumos’ ongoing R&D in enhancing its diagnostic technology platform, which is crucial for securing partnerships and advancing point-of-care technologies.
Lumos Diagnostics has achieved a significant milestone in its FebriDx CLIA waiver clinical study by enrolling its 500th patient, triggering a milestone payment from its partner BARDA. The study aims to secure a CLIA waiver from the U.S. FDA, which would allow broader use of FebriDx in various healthcare settings, potentially unlocking a U.S. market exceeding $1 billion. With the study expected to conclude by Q4 2025, Lumos plans to submit its CLIA waiver application in October 2025, which could enhance point-of-care decision-making and antibiotic stewardship in the U.S. healthcare system.
Lumos Diagnostics has announced that its FebriDx point-of-care test will be used in the University of Wollongong’s OPTIMAS-GP Trial, which aims to reduce unnecessary antibiotic prescribing for respiratory infections in primary care settings. This trial, funded by the Australian Government’s Medical Research Future Fund, will evaluate the feasibility and acceptability of FebriDx in Australian general practice, marking its first formal evaluation in this setting. The initiative is part of a broader effort to combat antimicrobial resistance by promoting evidence-based clinical decisions, and Lumos will provide approximately 2,000 test kits at a reduced cost.
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a change in its registered office and principal place of business to a new address in Melbourne, Australia. This move is part of the company’s ongoing efforts to streamline its operations and enhance its market presence, with all other contact details remaining unchanged.
Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx® test from a sixth Medicare Administrative Contractor (MAC), CGS Administrators, which covers Kentucky and Ohio. This achievement means Lumos now has reimbursement coverage from six out of seven MACs, representing over 85% of US Medicare payment coverage, significantly expanding its access to the Medicare patient population. This development is a critical milestone for Lumos, as Medicare often sets a precedent for private insurance payors, and it demonstrates the company’s commitment to achieving nationwide access and broad clinical adoption of FebriDx.
Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx test from a fifth Medicare Administrative Contractor (MAC), WPS Health Solutions, retroactive from May 1, 2025. This achievement means Lumos now has coverage from five of the seven MACs, covering over 70% of US Medicare payments, which significantly enhances its access to the Medicare patient population. The company is actively negotiating with the remaining two MACs and aims to secure reimbursement from private insurers, striving for nationwide access and broad clinical adoption of FebriDx.
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a significant purchase order for its FebriDx test from iMedical, Inc., marking the largest single order since the test’s launch. This order underscores the growing acceptance and demand for FebriDx in the US market, following its FDA clearance in July 2023 for aiding in the diagnosis of bacterial acute respiratory infections. The collaboration with iMedical, a company known for providing cost-saving solutions to healthcare facilities, is expected to enhance the market presence of FebriDx and improve health outcomes through advanced point-of-care technology.
Lumos Diagnostics Holdings Ltd. announced the issuance of 23,000,000 unquoted performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee motivation and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.
Lumos Diagnostics Holdings Ltd. has released an investor briefing for Q3 FY25, emphasizing that the information is solely for informational purposes and not intended as a basis for investment decisions. The document highlights the company’s focus on providing diagnostic solutions, but it also includes disclaimers regarding the accuracy and reliability of the information, emphasizing the inherent risks and uncertainties in market data and forecasts.
Lumos Diagnostics reported a revenue of US$3.5 million for the third quarter of FY25, marking a 21% increase from the previous quarter, although down 13% from the same period last year. The company saw significant growth in its services and product revenues, with notable developments including new distribution partnerships for FebriDx® in the U.S. and the expansion of the Hologic fFN project. The company also achieved successful audit results for its quality management system, and FebriDx® was added to the Medicare Fee Schedule, potentially enhancing its market reach.
Lumos Diagnostics has secured additional U.S. Medicare reimbursement coverage for its FebriDx® test from two more Medicare Administrative Contractors (MACs), First Coast Service Options and Noridian Healthcare Solutions. This achievement expands Lumos’ Medicare coverage to four out of seven MACs, covering over 55% of U.S. Medicare payments. This milestone is crucial for the commercial success of FebriDx, as Medicare adoption often influences private insurance payors’ decisions. Lumos continues to pursue coverage from the remaining MACs and private payors to achieve nationwide access and support broad clinical adoption.